Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Acute Myeloid Leukemia
Clinical trial register · United States · industry-sponsored

Acute Myeloid Leukemia Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9141 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Oct 2026, 03:16 UTC
9141
Studies in scope
industry-sponsored, all four open statuses
4966
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 28 Florida 21 New York 19 Texas 18 Illinois 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Taiho Oncology, Inc.5 AbbVie4 Orca Biosystems, Inc.3 Kura Oncology, Inc.2 Daiichi Sankyo2
State
California28 Florida21 New York19 Texas18 Illinois14
All 34 states
Target enrolment
to

Acute Myeloid Leukemia trials in the USA

39 of 9141 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
AbbVie
Phase 2/3
660
California, Florida, Georgia, Missouri, New York, Texas
2026-06-30
Recruiting
AbbVie
Phase 1
18
California, Georgia, New York, Tennessee, Texas
2026-05-20
Recruiting
Remedy Plan, Inc.
Phase 1
24
New York, Texas
2026-02-13
Recruiting
Daiichi Sankyo
Phase 2
130
Alabama, California, Maryland, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania
2025-07-18
Recruiting
Debiopharm International SA
Phase 1/2
154
California, Florida, Illinois, Michigan, New York, Ohio, Texas
2025-05-30
Recruiting
CERo Therapeutics Holdings, Inc.
Phase 1
18
California, Colorado, Tennessee, Texas, Washington
2025-04-07
Active, closed
Stemline Therapeutics, Inc.
Phase 2
85
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York
2025-01-14
Active, closed
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT05589896Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
Ossium Health, Inc.
Phase 1/2
12
California, Florida, Georgia, Michigan, Oregon, Tennessee, Texas, Utah
2024-08-16
Recruiting
Study of REM-422 in Patients With AML or Higher Risk MDS
NCT06297941Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
DrugREM-422
Remix Therapeutics
Phase 1
100
California, Florida, Massachusetts, New York, Texas
2024-04-26
Recruiting
GluBio Therapeutics Inc.
Phase 1
48
California, Kansas, New York, Texas
2024-01-11
Recruiting
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
NCT06034275Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
Vincerx Pharma, Inc.
Phase 1
36
Alabama, Ohio, Tennessee, Texas, Washington
2023-09-13
Recruiting
Kura Oncology, Inc.
Phase 1
420
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2023-07-18
Recruiting
Chordia Therapeutics, Inc.
Phase 1/2
225
Arizona, Florida, Illinois, Minnesota, New York, Texas, Virginia, Washington
2023-04-25
Recruiting
Taiho Oncology, Inc.
Phase 1
27
Texas
2022-12-23
Active, closed
Kite, A Gilead Company
Phase 1
24
California, Maryland, Massachusetts, New York, Texas
2022-11-28
Active, closed
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT05316701Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 3
187
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, New York
2022-06-21
Active, closed
Faron Pharmaceuticals Ltd
Phase 1/2
181
California, Connecticut, North Carolina, Texas
2022-06-02
Recruiting
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
NCT04872478Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Meryx, Inc.
Phase 1
50
Georgia, New York
2022-04-01
Active, closed
Bristol-Myers Squibb
Phase 2
19
Alabama
2022-01-17
Recruiting
Taiho Oncology, Inc.
Phase 1
18
Texas
2021-12-15
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
California, Florida, Pennsylvania, Texas, Wisconsin
2021-05-24
Active, closed
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
NCT04730258Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML
DrugsCFI-400945·Azacitidine
Treadwell Therapeutics, Inc
Phase 1/2
72
California, Kentucky, New York, Ohio, Texas
2021-04-16
Active, closed
Taiho Oncology, Inc.
Phase 1/2
101
California, Connecticut, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey
2021-02-09
Active, closed
Sellas Life Sciences Group
Phase 3
127
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, New York
2021-02-08
Active, closed
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847Myelodysplastic Syndrome, Acute Myeloid Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
170
Alabama, California, Colorado, Kansas, Kentucky, Massachusetts, Michigan, Missouri
2020-08-07
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
California, Connecticut, Florida, Georgia, Massachusetts, New Jersey, New York, North Carolina
2020-05-21
Recruiting
Edgewood Oncology Inc.
Phase 1
80
California, New York, Texas
2020-01-06
Recruiting
Celyad Oncology SA
Phase 1
27
Florida, Kansas
2019-11-25
Active, closed
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT04013685Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 1
155
California, Colorado, Florida, Georgia, Illinois, Kansas, Massachusetts, Michigan
2019-11-21
Active, closed
AbbVie
Phase 1/2
218
California, Florida, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2019-11-06
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia
DrugsCobicistat·Revumenib
Syndax Pharmaceuticals
Phase 1/2
447
California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts, Missouri
2019-11-05
By invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
DrugDecitabine
Taiho Oncology, Inc.
Phase 2
332
California, Florida, Illinois, Maryland, Michigan, Minnesota, New Jersey, New York
2019-09-30
Active, closed
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia
DrugsZiftomenib·Itraconazole·Midazolam
Kura Oncology, Inc.
Phase 1/2
263
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2019-09-12
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Arizona, California, Illinois, Massachusetts, Michigan, New Hampshire, Washington
2019-09-06
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide
CellCentric Ltd.
Phase 1/2
250
Georgia, Indiana, Maryland, Nebraska, Pennsylvania
2019-08-09
Active, closed
Precigen, Inc
Phase 1
88
Florida, Minnesota
2019-05-20
Recruiting
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT03802695Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Orca Biosystems, Inc.
Phase 1
300
California, Florida, Georgia, Kansas, New Jersey, New York, Ohio, Texas
2019-04-08
Active, closed
Daiichi Sankyo
Phase 1/2
65
California, Colorado, Delaware, District of Columbia, Georgia, Minnesota, Ohio, Pennsylvania
2018-08-15
Active, closed
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
NCT02665065Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute
Actinium Pharmaceuticals
Phase 3
153
Arizona, Connecticut, District of Columbia, Florida, Illinois, Iowa, Kansas, Minnesota
2016-06
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/acute-myeloid-leukemia

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,141 studies in total at the last sync on 17 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies listing the condition Acute Myeloid Leukemia.

How many Acute Myeloid Leukemia trials are recruiting in the US?

21 of the 39 studies on this page are recruiting new participants as of the 17 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Acute Myeloid Leukemia), 39 studies
PhaseStudiesRecruitingShare
Phase 1171343.6%
Phase 1/212530.8%
Phase 24110.3%
Phase 34010.3%
Phase 2/3225.1%

Most active sponsors

Lead sponsors with the most studies (Acute Myeloid Leukemia)
Lead sponsorStudiesRecruiting
Taiho Oncology, Inc.53
AbbVie42
Orca Biosystems, Inc.31
Daiichi Sankyo21
Kura Oncology, Inc.21
Actinium Pharmaceuticals10
BeOne Medicines11
Bristol-Myers Squibb10
CellCentric Ltd.11
Celyad Oncology SA11

Top states

Top states (Acute Myeloid Leukemia), by number of studies with a site there
StateStudies
California28
Florida21
New York19
Texas18
Illinois14
Georgia13
Massachusetts13
Michigan10
Colorado8
Minnesota7
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.